Your browser doesn't support javascript.
loading
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak, Daniel P; Vogelzang, Nicholas J; Budnik, Nikolay; Wiechno, Pawel Jan; Sternberg, Cora N; Doner, Kevin; Bellmunt, Joaquim; Burke, John M; de Olza, Maria Ochoa; Choudhury, Ananya; Gschwend, Juergen E; Kopyltsov, Evgeny; Flechon, Aude; Van As, Nicolas; Houede, Nadine; Barton, Debora; Fandi, Abderrahim; Jungnelius, Ulf; Li, Shaoyi; de Wit, Ronald; Fizazi, Karim.
Afiliación
  • Petrylak DP; Yale Cancer Center, Department of Medicine Division of Oncology, New Haven, CT, USA. Electronic address: daniel.petrylak@yale.edu.
  • Vogelzang NJ; US Oncology Research, Houston, TX, USA; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
  • Budnik N; NSHI Dorozhnaya Clinical Hospital of OAO Russian Railways, Rostov-on-Don, Russia.
  • Wiechno PJ; Department of Uro-Oncology, Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland.
  • Sternberg CN; San Camillo and Forlanini Hospitals, Department of Medical Oncology, Rome, Italy.
  • Doner K; Texas Oncology, Austin, TX, USA.
  • Bellmunt J; University Hospital del Mar-IMIM, Barcelona, Spain; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Burke JM; US Oncology Research, Houston, TX, USA; Rocky Mountain Cancer Centers, Aurora, CO, USA.
  • de Olza MO; Catalan Institute of Oncology, Department of Medical Oncology, Barcelona, Spain.
  • Choudhury A; Department of Clinical Oncology, The Christie NHS Foundation Trust and Institute of Cancer Sciences, University of Manchester, Manchester, UK.
  • Gschwend JE; Department of Urology, Rechts der Isar Medical Center, Technische Universität München, München, Germany.
  • Kopyltsov E; State Institution of Healthcare "Regional Clinical Oncology Dispensary", Omsk, Russia.
  • Flechon A; Centre Léon Bérard, Department of Medical Oncology, Lyon, France.
  • Van As N; Department of Clinical Oncology, Royal Marsden Hospital, London, UK.
  • Houede N; Medical Oncology Department, Groupe Hospitalier Universitaire Caremeau Place du Professeur Robert Debré, Nîmes, France.
  • Barton D; Celgene Corporation, Summit, NJ, USA.
  • Fandi A; Celgene Corporation, Summit, NJ, USA.
  • Jungnelius U; Celgene Corporation, Summit, NJ, USA.
  • Li S; Celgene Corporation, Summit, NJ, USA.
  • de Wit R; ErasmusMC Cancer Institute, Rotterdam, Netherlands.
  • Fizazi K; Institut Gustave Roussy, Department of Cancer Medicine, University of Paris Sud, Villejuif, France.
Lancet Oncol ; 16(4): 417-25, 2015 Apr.
Article en En | MEDLINE | ID: mdl-25743937
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Taxoides / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Taxoides / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article Pais de publicación: Reino Unido